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E-mail: derek.mann@newcastle.ac.ukThe progression of fibrosis in chronic liver disease is dependent
upon hepatic stellate cells (HSCs) transdifferentiating to a my-
ofibroblast-like phenotype. This pivotal process is controlled by
enzymes that regulate histone methylation and chromatin
structure, which may be targets for developing anti-fibrotics.
There is limited pre-clinical experimental support for the po-
tential to therapeutically manipulate epigenetic regulators in
fibrosis. In order to learn if epigenetic treatment can halt the
progression of pre-established liver fibrosis, we treated mice
with the histone methyltransferase inhibitor 3-deazaneplano-
cin A (DZNep) in a naked form or by selectively targeting
HSC-derived myofibroblasts via an antibody-liposome-DZNep
targeting vehicle. We discovered that DZNep treatment in-
hibited multiple histone methylation modifications, indicative
of a broader specificity than previously reported. This broad
epigenetic repression was associated with the suppression of
fibrosis progression as assessed both histologically and bio-
chemically. The anti-fibrotic effect of DZNep was reproduced
when the drug was selectively targeted to HSC-derived myofi-
broblasts. Therefore, the in vivo modulation of HSC histone
methylation is sufficient to halt progression of fibrosis in the
context of continuous liver damage. This discovery and our
novel HSC-targeting vehicle, which avoids the unwanted effects
of epigenetic drugs on parenchymal liver cells, represents an
important proof-of-concept for epigenetic treatment of liver
fibrosis.
INTRODUCTION
Fibrosis is a pathology associated with aging, chronic disease, and a
variety of connective tissue disorders, including arthritis, systemic
scleroderma, and athrofibrosis.1 The development of fibrosis in a
tissue arises from remodelling of connective tissue and the net depo-
sition of a collagen-rich fibril-forming extracellular matrix (ECM).
Fibrotic remodelling is often a progressive process culminating in
architectural and functional disruption of the affected tissue; in the218 Molecular Therapy Vol. 25 No 1 January 2017 ª 2017 The Author(s).
This is an open access article under the CC BY license (http://creativeccase of vital tissues, such as the liver, lung, heart, or kidney, fibrosis
may lead to organ dysfunction and early mortality. Fibrosis also es-
tablishes microenvironments in which cancers are more likely to
emerge, an example being liver fibrosis and/or cirrhosis, which is a
major risk factor for hepatocellular carcinoma.2 At the present
time, there is a lack of clinically proven effective antifibrotic drugs;
the exception being Pirfenidone, now approved for treatment of
idiopathic pulmonary fibrosis.3 There is, therefore, an urgent need
to develop novel therapeutic strategies that either suppress fibrosis
or promote fibrosis regression.
Myofibroblasts are the major cell type responsible for deposition and
maintenance of the fibrotic ECM irrespective of the tissue type or the
underlying cause of damage.4,5 The majority of myofibroblasts are
generated locally in response to tissue injury, which usually occurs
via the transdifferentiation of precursor cells, such as pericytes or
resident fibroblasts, or by the process of epithelial-to-mesenchymal
transition.6,7 A normal wound healing response is self-limiting to
enable subsequent tissue regeneration, and this response is associated
with clearance of myofibroblasts by apoptosis or reversal of trans-
differentiation.8–10 However, in the context of repeated tissue injury
or unresolved chronic inflammation, myofibroblasts persist and
establish autocrine signaling pathways that stimulate their survival,
proliferation, migration, and continued production of fibrotic ECM.
The persistence of tissue myofibroblasts is a common feature of
progressive fibrosis and a major driver of disease progression.4
Furthermore, myofibroblasts within the fibrotic matrix can beommons.org/licenses/by/4.0/).
www.moleculartherapy.org“activated” toward a highly proinflammatory state in response to
epithelial stress; this indicates that fibrosis-associated myofibroblasts
become orchestrators of inflammation within the diseased tissue.11
Myofibroblasts are therefore key therapeutic targets in fibrosis, but
a major challenge is to identify safe and efficacious drug targets that
selectively modulate myofibroblast biology.
Transdifferentiation of resident liver sinusoidal hepatic stellate cells
(HSCs) intomyofibroblasts is tightly regulated by epigeneticmodifica-
tions, including relandscaping of the DNAmethylome and chromatin
remodelling at genes regulating the myofibroblast phenotype.12–14
EZH2 is the catalytic component of the polycomb repressor 2 complex
responsible for methylation of histone 3 lysine 27 (H3K27) and is
required for stimulating enrichment of the repressive H3K27me3
mark.14 Enrichment of H3K27me3 at the PPARg gene is a funda-
mental epigenetic modification during HSC transdifferentiation that
brings about transcriptional repression of PPARg; this is an essential
step for the cell to acquire its myofibroblastic phenotype. Indeed,
forced expression of PPARg in liver myofibroblasts is sufficient to
repress collagen expression and reprogram the HSC phenotype to
resemble its precursor quiescent state.15 Small-molecule inhibitors
of EZH2, including GSK126, EPZ-6438, and 3-deazaneplanocin A
(DZNep), have been proposed for therapeutic development in
cancer.16–18 We have previously reported in vitro experiments that
show that DZNep can irreversibly suppress classic morphological
and biochemical changes associated with HSC transdifferentiation.14
Similar studies in lung myofibroblasts have confirmed that inhibition
of EZH2 suppresses their fibrogenic phenotype and decreases collagen
production.19 However, the potential for in vivo inhibition of EZH2 as
an antifibrotic strategy has not been determined.
In a well-established in vivo model of HSC transdifferentiation and
liver fibrosis, we show that therapeutic administration of DZNep in
the context of pre-established liver disease is able to effectively
suppress progression of fibrosis despite continued liver damage.
Moreover, we have developed an antibody-liposome-targeting vehicle
that can specifically deliver encapsulated molecules to liver myofibro-
blasts.20 Incorporation of targeting antibody into the surface liposome
is a novel approach that further develops liposomal technology that
was previously used to deliver agents for experimental treatment of
liver fibrosis.21–24 We demonstrate that in vivo application of this
novel targeting approach achieves selective inhibition of the
H3K27me3 mark in myofibroblasts and halts progression of fibrosis.
Our findings provide an exciting proof-of-concept for the use of
emerging epigenetic drugs in the treatment of fibrosis in chronic dis-
ease and highlight the therapeutic potential of targeting EZH2 and
potentially other profibrogenic histone lysine methyltransferases
(HKMTs).
RESULTS
DZNep andRelated Purine Analogs Suppress Induction of Type I
Collagen Expression
DZNep is a purine nucleoside analog (PNA), which is in a family of
compounds, many of which are being used clinically and have beenproven to be effective in the treatment of hematological malignancies
and autoimmune disorders.33 In a blinded fashion, we began by deter-
mining the ability of several chemically-related PNAs (designated
compounds 1–9; Figure S1) to inhibit HSC expression of transcripts
for the profibrogenic genes collagen 1A1, aSMA, and TIMP-1. This
experiment was carried out in vitro using the widely adopted cell-
culture model of HSC transdifferentiation in which freshly isolated
primary rodent HSCs are cultured for several days in complete
serum-containing media. In this model, HSCs undergo a similar pro-
cess of transdifferentiation to that described in vivo, which serves as a
robust tool for pre-clinical drug discovery.34 The drugs were added to
HSCs that had been freshly isolated from normal rat liver and
cultured on plastic in complete serum-containing media for just
1 day, at which point the cells had not yet undergone transdifferentia-
tion. Based on results from our previous studies, the compounds were
tested at a single concentration of 1 mg/mL in each case. After a
further 6 days, at which point HSCs had adopted the myofibroblast
phenotype, cultures were harvested and was RNA isolated for qRT-
PCR analyses of gene expression. Compounds 3, 4, 5, and 8 were
found to repress collagen 1A1 gene expression; compounds 1 and 3
repressed aSMA gene expression, while compound 2 showed the
overall best antifibrogenic performance by inhibiting collagen 1A1,
aSMA, and TIMP1 gene expression (Figures 1A–1C). Decoding the
experiment revealed that compound 2 was DZNep which, in addition
to suppressing expression of all three fibrogenic genes, was confirmed
to prevent cultured HSCs from adopting the morphology of an acti-
vated myofibroblast (Figure 1D). Furthermore, culturing of quiescent
HSCs (qHSCs) in the presence of DZNep resulted in increased
apoptosis in day 7 cells (Figures 1E and 1F, left panel) while also
reducing proliferation (Figure 1F, right panel). These data indicate
that PNAs are a class of compounds with strong potential for antifi-
brotic activities and confirm that DZNep is a molecule worthy of
in vivo investigations.
DZNep Prevents the Progression of Carbon
Tetrachloride-Induced Liver Fibrosis
Repetitive exposure of the liver to the hepatotoxin carbon tetra-
chloride (CCl4) establishes repeated rounds of liver damage and
inflammation, which drives a progressive fibrogenic process chiefly
mediated by the activities of myofibroblasts generated from an HSC
origin.10 To determine the in vivo antifibrotic properties of DZNep,
adult male C57Bl6 mice were injured with CCl4 for 2 weeks in order
to establish mild fibrosis and were subsequently therapeutically
administered DZNep (or vehicle control) over a further 6 weeks while
being continually injured with CCl4 (Figure 2A) Sirius Red staining of
liver sections (Figure 2B) and morphometric analysis (Figure 2C)
showed the expected progressive accumulation of cross-linked
fibril-forming collagens between weeks 2 and 8. Remarkably, this dis-
ease progression was attenuated in mice treated with DZNep (Figures
2B and 2C). Staining for aSMA again revealed the expected time-
dependent increase in the numbers of myofibroblasts when
comparing the 2- and 8-week control groups; however, DZNep treat-
ment prevented this accumulation of scar-forming myofibroblasts
(Figures 2D and 2E). There were no significant changes in the numberMolecular Therapy Vol. 25 No 1 January 2017 219
Figure 1. Purine Nucleoside Analogs Demonstrate Varied Ability to Inhibit HSC Transdifferentiation In Vitro
(A–C) Freshly isolated rat HSCs were grown for 7 days in the presence of 1 mg/mL each of a series of chemically related PNAs (designated compounds 1–9). The cells were
harvested on day 7, and transcripts for collagen I (A), aSMA (B), and TIMP-1 (C) were quantified by qPCR in at least four separate preparations of HSCs. The best-performing
drug across all assays is in gray (compound 2). The line on the bar graphs shows the level of gene expression in control cells. Error bars represent mean ± SEM. RLTD, relative
level of transcriptional difference. (D) Representative photomicrographs showing morphological differences between day 7 control-activated HSCs or equivalent culture
grown in the presence of 1 mg/mL compound 2 (deazaneplanocin A). (E) Representative FITC (left), rhodamine (middle), and merged (right) fluorescent images of acridine
orange-stained day 7 control-activated HSCs or equivalent culture grown in the presence of 1 mg/mL compound 2 (deazaneplanocin A). (F) Graphs showing average
percentage of apoptotic cells (left panel) and number of proliferating cells (MTT assay, right panel).
Molecular Therapyof macrophages observed between the groups (Figure 2F). Quanti-
fication of hepatic transcripts at 8 weeks confirmed the anticipated
time-dependent increases in expression of fibrogenic collagen 1A1
(Figure 2C), aSMA (Figure 2E), CTGF, TIMP-1 (Figure 2G), IL-6,
and transforming growth factor b1 (TGF-b1) (Figure 2H) in control
mice. By contrast, in DZNep-treated mice, levels of these transcripts
were similar to those measured at 2 weeks, thus reflecting the repres-
sive effect of the drug on accumulation of aSMA+ cells. There were no
significant changes in expression of vascular endothelial growth fac-220 Molecular Therapy Vol. 25 No 1 January 2017tor (VEGF) or angiopoetin 1 in any of the groups (Figure S2). To
ascertain broader effects of DZNep on gene expression, we carried
out an unbiased microarray analysis of the hepatic transcriptome
comparing the 8-week vehicle control group to the DZNep-treated
group (Figure 3). DZNep increased the expression of 248 genes and
decreased expression of 108 genes (Tables S1 and S3). The heatmap
in Figure 3A shows replicates for the top 15 most upregulated and
downregulated genes, while Figures 3B and 3C provide validatory
qRT-PCRs for a subset of the downregulated and upregulated genes,
(legend on next page)
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Molecular Therapyrespectively. Of particular note, among the downregulated genes were
Acta2 (aSMA) and CTGF, confirming the qRT-PCR data; the tran-
scription factor EGR1 was also downregulated, which plays a core
role in fibrogenesis by positively regulating the expression of multiple
fibrogenic growth factors, including TGF-b1, platelet-derived growth
factor (PDGF), and fibroblast growth factor (FGF).35 Strongly upre-
gulated genes were enriched for those encoding enzymes involved
in the metabolism of xenobiotics or bile acids (Cyp2c37, Cyp2c50,
Cyp7a1, Cyp8b1, and Inmt), lipids (Acss2 and Thrsp1), iron
(Hamp2), and glucose (G6Pc). However, alanine transaminase
(ALT) values were not significantly different between the control of
DZNep-treated groups, indicating that the drug does not display
any obvious hepatotoxicity over and above that caused by CCl4
and, further, that the observed changes in expression of metabolic
genes did not cause any interference with CCl4-induced liver damage
(Figures S3A and S3B). Notably, expression of Cyp2E1, which metab-
olises CCl4 in the liver, remained unchanged in this model
(Figure S4).
DZNep Acts as a Broad Specificity Inhibitor of Hepatic Histone
Methyltransferases
To confirm that the antifibrogenic activity of DZNep was associated
with the expected in vivo repression of the H3K27me3 epigenetic
mark controlled by EZH2, we carried out western blotting using
protein extracts from 8-week vehicle control and DZNep-treated
livers. Relative to vehicle controls, a loss of hepatic H3K27me3 was
associated with DZNep treatment in the CCl4 models (Figure 4A).
However, we also observed a loss of other histone modifications,
including epigenetic marks associated with transcriptional activation
(H3K36me3 and H3K4me3) and repression (H3K9me3) (Figure 4A).
These data support previous results, indicating a broader effect of
DZNep on histone lysine methyltransferase activities than suggested
in earlier reports, which claimed specificity of the drug for EZH2.18
Furthermore, free DZNep was repressing H3K27 trimethyation in
multiple hepatic cell types in addition to HSCs, including hepatocytes
and cholangiocytes (Figure 4B).
Targeting of DZNep to HSC-Derived Myofibroblasts Inhibits
Fibrosis
Given the broad inhibitory effects of DZNep on histone lysine meth-
yltransferases (HKMTs) and the suggestion from hepatic mRNA
expression data of potential metabolic effects on hepatocytes, it was
plausible that the observed anti-fibrotic activities of the drug might
not reflect a direct activity in HSCs. To address this important caveat,Figure 2. DZNep Prevents Fibrosis Progression in a Chronic Model of CCl4-Ind
(A) Schematic representation of chronic CCl4 model of liver fibrosis combined with pro
injections, whereas blue arrows show DZNep injections. Briefly, liver fibrosis was establis
further 6weeks. (B) Histological sections showing collagen staining (Sirius Red). (C) Grap
1A1 as quantified by qPCR in livers from all animals in the study (right). (D) aSMA staining
starting point of treatment (2 weeks CCl4). (E) Graphs showing average percentage area
(right). (F) Histological sections showing macrophage staining (F4/80, left panels) an
(G) mRNA levels for XTGF, TIMP1, (H) IL6, and TGFb1 as quantified by qPCR in l
**p < 0.01; ***p < 0.001.
222 Molecular Therapy Vol. 25 No 1 January 2017we exploited recent advances in liposome-mediated drug delivery,
ligand-mediated cell targeting of liposomes, and the specificity of
the single chain antibody (ScAb) C1-3 for HSC-derived myofi-
broblasts.36,37 C1-3 specifically recognizes synaptophysin, a trans-
membrane protein that is selectively expressed on HSC-derived
myofibroblasts in the diseased liver.38 We therefore asked if targeted
delivery of DZNep to HSC-derived myofibroblasts in C1-3-coated li-
posomes could bring about a similar therapeutic effect as that
observed with free DZNep. Prior to answering this question, we first
confirmed the specificity of C1-3-liposome conjugates for liver myo-
fibroblasts. To this end, the cytotoxic drug doxyrubicin (Dox) was
incorporated into liposomes as detailed in the Materials and Methods
(and summarized in Figure S5). Dox-liposomes were subsequently
separated from free Dox by purification over a Sephadex G50 column.
Critically, the Dox-liposome complexes were constructed from lipid
conjugates, which included a DSPE-PEG2000-MAL group in which
the maleimide terminus could be used for coupling to targeting
proteins.26 We exploited this chemistry to couple Dox-liposomes to
C1-3 or a control (CSBD9) ScAb, the latter lacking specificity for
myofibroblasts. ScAb-Dox-liposomes were then administered to
mice undergoing acute injury with a high dose of CCl4 in which
HSCs were stimulated to undergo myofibroblast transdifferentiation
(Figure 5A). Relative to control liposomes, C1-3-Dox-liposomes had
no effect on CCl4-induced serum ALT, AST, and ALP values, indi-
cating no obvious impact on hepatocyte death (Figure S6). C1-3-
Dox-liposomes had no effect on the number of hepatic macrophages,
neutrophils, or proliferating hepatocytes (Figures 5B–5D). In
contrast, livers of C1-3-Dox-liposomes had roughly half the number
of aSMA+ myofibroblasts compared with controls (Figure 5E), and
this was associated with reduced hepatic expression of TGF-b1 (Fig-
ure 5F). These data provided us with confidence that C1-3-liposomes
provide an effective vehicle for in vivo delivery of encapsulated drugs
selectively to HSC-derived myofibroblasts. We next generated
C1-3-DZNep-liposomes together with a control vehicle CSBD9-
DZNep-liposomes. To determine the in vivo therapeutic potential
of DZNep-liposome-C1-3 conjugates, they were administered to
mice under a similar experimental CCl4 therapeutic model as previ-
ously described for free DZNep.Mice were initially injured for 2weeks
to establish liver disease, prior to a further 6 weeks of injury, during
which time the animals were administered either C1-3-DZNep-lipo-
somes or control CSBD9-DZNep-liposomes (Figure 6A). After
8 weeks, mice were culled, and all liver sections were stained with
Sirius red for collagen and by immunohistochemistry for aSMA (Fig-
ures 6B and 6C). As shown in Figures 6B and 6C, significantly lessuced Liver Fibrosis
gressive therapeutic treatment with DZNep. Grey arrows show frequency of CCl4
hed for 2 weeks followed by administration of DZNep treatment alongside CCl4 for a
hs showing average percentage area for Sirius Red (left) andmRNA levels of Collagen
in three representative control or DZNep-treated animals as well as the animals at the
aSMA in all groups (left) and mRNA levels of aSMA as quantified by qPCR in livers
d graphs showing average number of F4/80 positive cells per field (right panel).
ivers of all animals. Error bars in relevant panels represent mean ± SEM. *p < 0.05;
Figure 3. DZNep Alters Expression of Numerous
Genes in a Chronic Model of CCl4-Induced Liver
Fibrosis
(A) A heatmap displaying results of microarray carried out
using four control and four DZNep-treated livers from a
chronic model of CCl4-induced liver fibrosis. The top 15
most upregulated and downregulated genes are shown.
Blue, negative values (i.e., downregulated); red, positive
(upregulated); yellow, unchanged. (B) mRNA level of Slpi
and (C) Hamp2, G6pc, and Thrsp genes was quantified by
qPCR in order to validate the results of microarray. Error
bars in relevant panels represent mean ± SEM. **p < 0.01;
***p < 0.001.
www.moleculartherapy.orgfibrotic collagen accumulated in the livers of mice receiving C1-3-
DZNep-liposomes compared with those treated with control
CSBD9-DZNep-liposomes. This difference in fibrosis was reflected
in associated levels of hepatic aSMA, which were lower in livers of
C1-3-DZNep-liposome recipients (Figure 6C, right panel). Targetted
DZNep also resulted in a significant reduction of collagen 1A1,
CTGF, and angiopoetin 1 expression (Figure 6D), while no change
was detected in the expression of TIMP1 (Figure S7). We conclude
that in vivo targeting of DZNep to HSCs using a C1-3-liposome
vehicle leads to a reduction in the number of hepatic myofibroblasts
in diseased livers, suppression of collagen deposition, and reduced
levels of hepatic fibrosis.
To show specificity of C1-3-DZNep-liposome treatment for hepatic
myofibrobalsts, we stained the livers of C1-3-DZNep-liposomes and
control CSBD9-DZNep-liposomes for the presence of an
H3K27me3 epigenetic mark (Figure 7A). Data showed the absenceof H3K27me3 staining only in myofibroblasts in
the livers of mice receiving C1-3-DZNep-lipo-
somes, while mice treated with control CSBD9-
DZNep-liposomes showed the presence of
H3K27me3 in all cell types, including myofibro-
blasts (Figure 7A). Dual immunofluorescence
staining of livers for aSMA and H3K27me3
further confirmed that treatment with C1-3-
DZNep-liposomes is associated with selective
loss of the epigenetic mark in myofibroblasts
(Figure 7B).
DISCUSSION
The concept of epigenetic therapy is now
well-established in the field of oncology, with
the successful clinical application of inhibitors of
DNA methylation (e.g., decitabine) and histone
deacetylases (e.g., SAHA) described for many
types of cancers.39 Akin to cancer, fibrosis is a pa-
thology that is associated with dramatic changes
in tissue architecture underpinned by alterations
in cell differentiation, fate, and function. In
particular, the generation, proliferation, and life-span of myofibroblasts, the major cellular drivers of extracellular ma-
trix deposition, are important determinants of fibrosis progression.40
Chronic disease is often characterized by an unresolved wound-heal-
ing process in which tissue myofibroblasts are continually produced
and become highly proliferative, motile, and resistant to apoptosis.8,40
The behavioral parallels of myofibroblasts to those of neoplastic cells,
in particular, their proliferative nature and resistance to apoptosis,
have led our group and other investigators to explore the possibility
that epigenetic alterations may regulate their phenotype and behavior
and, in turn, the course of the fibrogenic process.41 Transdifferentia-
tion of HSCs represents the major cellular source of myofibroblasts in
chronic liver disease and is associated with global changes in gene
expression underpinned by re-landscaping of the HSC epigenome,
including genome-wide changes in DNA methylation and histone
modifications.12,13,42 Previous in vitro studies and a small number
of in vivo studies have demonstrated the ability of pharmacological
inhibitors of DNA methylation, histone deacetylation, and histoneMolecular Therapy Vol. 25 No 1 January 2017 223
Figure 4. DZNep Inhibition of Histone Methylation Is Not Specific to
H3K27me3
(A) 30 mg whole-cell protein from six livers of control animals or six livers from DZNep-
treated livers within the chronic model of CCl4-induced liver fibrosis were im-
munoblotted for H3K36me3, H3K4me3, H3K27me3, H3K9me3, and b-actin.
(B) Histological sections showing H3K27me3 staining in a representative set of vehicle
orDZNep-treated chronicCCl4 livers.Brownarrows show the presence ofH3K27me3
staining in hepatocytes and biliary epithelial cells of vehicle-treated fibrotic livers, with
H3K27me3 markedly absent in both cell types in DZNep-treated livers.
Molecular Therapymethylation to suppress in vivo and culture-induced HSC transdiffer-
entiation as well as development of fibrosis.12,14,43–47 The potential for
epigenetic approaches to be exploited for suppressing fibrosis is also
supported by in vivo investigations with mice lacking the master
epigenetic regulator MeCP2, which is attenuated for fibrosis across
multiple tissues, including liver, lung, heart, and retina.14,48–52 The
work we have described in this present study significantly advances
these previous investigations by showing that in vivo administration
of the epigenetic drug DZNep halts the progression of pre-established
experimental liver fibrosis despite sustained liver damage. Remark-
ably, we were able to demonstrate that this anti-fibrotic activity of
DZNep is retained when the drug is selectively targeted to HSC-
derived myofibroblasts, thus providing the first proof-of-concept224 Molecular Therapy Vol. 25 No 1 January 2017that progressive tissue fibrosis can be therapeutically attenuated via
the direct epigenetic manipulation of the myofibroblast.
A major target of DZNep is EZH2, the only HKMT in nature that
catalyzes trimethylation at H3K27.53 EZH2 is aberrantly expressed in
numerous cancers, including leukemia, pancreatic ductal adeno-
carcinoma, and hepatocellular carcinoma, and there are now many
pre-clinical studies reporting the inhibitory effects ofDZNep on tumor
growth.54,55 Treatment of cells with DZNep results in depletion of
EZH2 and, as such, this effect and the associated loss of the
H3K27me3 mark is considered to be its major mechanism of anti-tu-
mor activity.However, we report that in vivo administration ofDZNep
has broader inhibitory effects on histone 3 methylation in the liver,
with global diminution of H3K4me3, H3K9me3, and H3K36me3 as
well as the anticipated loss of H3K27me3. This non-selective effect
of DZNep on histonemethylation has previously been described using
in vitro cancer cell models where the drug suppressed both repressive
and active histone methylationmarks.18 On the one hand, a drug such
as DZNep, which has a global impact on histone methylation, may be
clinically adventitious since HSC transdifferentiation requires the de
novo annotation of multiple repressive and activatory histone methyl-
ationmarks, thus reflecting the need to repress the expression of genes
that promote the adipogenic phenotype of quiescent HSCs while
simultaneously programming the transcription of genes that are
characteristic of the myofibroblast phenotype.12–14 As an example,
de novo expression of MeCP2 is induced shortly after HSCs are plated
into culture and leads to the almost simultaneous de novo expression of
EZH2 and ASH1 which, combined, stimulate H3K27me3-mediated
repression of anti-fibrogenic PPARg and H3K4me3-regulated tran-
scription of pro-fibrogenic TGF-b1, TIMP-1, and type I collagen I
genes.13,14 On the other hand, a systemic repression of histonemethyl-
ation in the context of a long-term therapeutic regimenwould be likely
to result in unwanted side effects, as might the global loss of EZH2
expression. In this regard, DZNep-mediated suppression of EZH2
has been reported to enhance lipid accumulation and inflammation
in high-fat diet models of rodent liver disease.56 One solution to this
problem explored here is the use of a myofibroblast-targeting vehicle
to achieve in vivo cell-selective delivery of DZNep. This aim was
achieved by initially showing that liposomes coated with the HSCs tar-
geting ScAb C1-3 and loaded with the cytotoxic drug doxyrubicin
selectively depleted aSMA+ liver myofibroblasts. We then demon-
strated that therapeutic administration of C1-3-coated liposomes car-
rying DZNep halted fibrosis progression in the CCl4 model with a
similar efficacy to that achieved when administering “naked” DZNep.
This approach supports our hypothesis that in vivo therapeutic effects
of DZNep are a consequence of direct targeting of epigenetic events in
liver myofibroblasts rather than being due to effects on other types of
liver cells. We propose that this myofibroblast-selective drug delivery
technology may be developed for other therapeutic compounds that
have the potential to effect a broad number of cell types and, in partic-
ular, for epigenetic drugs thatmodulate chromatinmodifications com-
mon tomore than one type of liver cell. It is important to note that the
basic liposome vehicle we have used lends itself to the incorporation of
a wide number of therapeutic molecules, including small drug-like
Figure 5. Liposomes Coated with C1-3 ScAb and Loaded with Doxorubicin Significantly Decrease Numbers of Hepatic Myofibroblasts
(A) Schematic representation of acute CCl4 model of liver fibrosis and therapeutic treatment with C1-3/Dox liposomes. (B) Representative histological sections and graph
showing average number of NIMP+ cells (neutrophils), (C) F4/80 (macrophages), and (D) PCNA in control (C1-3/empty liposomes) or C1-3/doxorubicin liposomes treated
livers. (E) aSMA staining in representative control (C1-3/empty liposomes) or C1-3/doxorubicin liposome-treated animals and average aSMA positive area in both groups of
livers. (F) mRNA levels of TGF-b1 as quantified by qPCR in livers of control (C1-3/empty liposomes) and C1-3/doxorubicin liposome-treated animals. Error bars in relevant
panels represent mean ± SEM. *p < 0.05.
www.moleculartherapy.orgcompounds, modulatory RNAs and DNAs, antibodies, and peptide-
based molecules, all of which can theoretically be encapsulated into
the vehicle without the need for chemical modifications. A second
solution to the problem of specificity of epigenetic therapeutics that
is being actively pursued in both academic and industrial groups is
the design of highly selective HKMT inhibitors.57 It is anticipated
that we will shortly have available a toolbox of drug-like molecules
that have a high degree of specificity for a particular histone-modifying
enzyme. As an example, BIX01294 (BIX) is a potent and selective in-
hibitor of the G9a and GLP members of the SUV39 family of H3K9
methyltransferases that has been shown to attenuate fibrosis in the
experimental unilateral ureteral obstruction (UUO) renal disease
model.58
In summary, we have used the epigenetic inhibitor DZNep in models
of pre-established chronic liver disease to establish the concept thatprogression of liver fibrosis can be manipulated by the pharma-
cological targeting of epigenetic modifications in myofibroblasts.
With this proof-of-concept, there is now a rational basis for the
screening of emerging “epi-drugs” as potential anti-fibrotics for either
halting or even reversing the fibrotic process in the absence of an
effective treatment for the underlying cause of liver damage.
MATERIALS AND METHODS
Ethics
We hold appropriate licenses for animal experiments, which were
issued and/or approved by the local ethical committee and UK
Home Office.
Cell Culture
HSCs were isolated from normal livers of 350-g adult male Sprague-
Dawley rats by sequential perfusion with collagenase and pronase,Molecular Therapy Vol. 25 No 1 January 2017 225
Figure 6. Liposomes Coated with C1-3 ScAb and Loaded with DZNep Significantly Reduce Fibrosis in a Chronic CCl4 Model of Liver Fibrosis
(A) Schematic representation of the chronic CCl4 model of liver fibrosis combined with progressive treatment with ScAb/DZNep liposomes. Briefly, liver fibrosis was
established for 2 weeks, then the control ScAb CSBD9 or C1-3-coated DZNep-loaded liposomes were administered to animals alongside CCl4 for a further 6 weeks.
(legend continued on next page)
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www.moleculartherapy.orgfollowed by discontinuous density centrifugation in 11.5% Optiprep
(Life Technologies). HSCs were cultured on plastic in DMEM
supplemented with penicillin 100 U/mL, streptomycin 100 mg/mL,
l-glutamine 2 mmol/L, and 16% fetal calf serum and were
maintained at 37C in an atmosphere of 5% CO2. Activated HSCs
were generated by continuous culture of freshly isolated cells on
plastic for 7 days.
Small-Molecule Inhibitors of HSC Activation
Nine proprietary compounds were obtained fromD.C.K.C. and tested
on day 1 quiescent HSCs in a range of concentrations for their ability
to prevent HSC activation in vitro (Figure S1). A concentration of 1
ug/mL was used in the experiments shown. Compounds were applied
on quiescent HSCs 12 hr after the isolation, and cells were later har-
vested at time intervals as indicated.
Histology and/or Immunohistochemistry
Mouse liver tissue was fixed in 10% formalin in PBS, and staining was
performed on formalin-fixed paraffin-embedded liver sections. Sirius
red staining was performed as previously described.25 aSMA and
H3K27me3 staining was carried out by blocking the endogenous
peroxidase activity with 2% hydrogen peroxide in methanol, and
then antigen retrieval was achieved using citiric saline antigen un-
masking solution (Vector Laboratories). Tissue was blocked using
an Avidin/Biotin Blocking Kit (Vector Laboratories) followed by
20% swine serum in PBS and then incubated with primary antibodies;
anti-aSMA antibody at 1:1000 (F3777 Sigma) or anti-H3K27
antibody was used at 1:200 (C15410195, diagnode) overnight at
4C. The next day, slides were PBS washed and then incubated
with biotinylated goat anti-fluorescein 1:300 (BA-0601 Vector) or
biotinylated swine anti-rabbit 1:200 (eo353 Dako), followed by
Vectastain Elite ABC Reagent. Antigens were visualized using a
DAB peroxidase substrate kit and counterstained withMayer’s hema-
toxylin. Slides were imaged using a Nikon ECLIPSE Ni-U (Nikon)
microscope, and blinded image analysis of 10 fields at 10 magnifi-
cation was performed using Nikon Imaging Software Elements Basic
Research (NIS-Elements).
For dual aSMA and H3K27me3 staining, slides were treated with
citiric saline antigen unmasking solution, then incubated in 0.1%
saponin for 10 min. Slides were then PBS washed, blocked with 1
casein and BSA for 60min, and then incubated with themousemono-
clonal anti-alpha smooth muscle actin FITC conjugated antibodies
(Sigma, F3777; dilution factor 1:50) and rabbit anti-H3K27me3 anti-
bodies (dilution factor 1:50) overnight at 4C. The next morning,
slides were PBS washed and incubated with anti-rabbit tetramethylr-
hodamine (TRITC) secondary Ab (1:100) for 2 hr. Counterstain was
performed using 0.3% sudan black in 70% ethanol (EtOH) prior to
incubating with DAPI special formulation NucBlue live ready probes(B) Histological sections showing collagen staining (Sirius Red) in a representative contro
area stained with Sirius Red. (C) Histological sections showing aSMA staining in a repre
percent positive area stained with anti aSMA antibody. (D) mRNA levels of Collagen 1
C1-3/DZNep liposome-treated animals. Error bars in relevant panels represent mean ±reagent (Life Technologies) for 10 min at room temperature. The
slides were then mounted with ProLong Gold antifade reagent (Life
Technologies). Images were taken using a Leica TCS SP2 UV AOBS
MP confocal microscope.
DZNep Liposomal Preparation
Liposomes were synthetized from HSPC:CHE:DSPE-PEG2000:
DSPE-PEG2000-MAL, 2:1:0.06:0.04 molar ratio, respectively. Lipids
were dissolved in chloroform at 10 mM and lipids and DZNep
were combined at the molar ratio of 11:1. Subsequently, PBS was
added, and the mixture was vortexed and then emulsified by soni-
cation for 5 min (200 W) at 4C using a probe sonicator (Sonica-
tor-ultrasonic liquid processor XL, Misonix). The mixture was
then processed by reverse-phase evaporation using a rota-evapo-
rator (Laborota 4000 Heidolph, Asynt) to remove the organic phase
by rotary evaporation under a stream of N2 until the system re-
verted to the aqueous phase. Following hydration in PBS, liposomes
were extruded (LiposoFast-basic extruder, Avestin) through a series
of polycarbonate filters of pore size ranging from 400 nm down to
100 nm. Free DZNep was separated from liposomes by passing lipo-
somes over a Sephadex G-50 column pre-equilibrated in PBS.
Finally, C1-3 or CSDB9 single-chain variable fragment (ScFvs) are
coupled to the maleimide terminus of DSPE-PEG2000-MAL using
the previously described methods for whole antibodies and for
Fab’ fragments coupling with slightly modifications.26 Briefly, to
activate the C1-3 and CSBD9 fragments for reactivity toward the
maleimide, we utilized 2-iminothiolane (Traut’s reagent) to convert
exposed amino groups on the antibody into free sulfhydryl groups.
A 20:1 mole ratio of 2-iminothiolane to ScFvs and 1 hr of incuba-
tion at room temperature with occasional mixing gave optimal ScFv
activation. After separation of thiolated ScFvs from iminothiolane
with the use of Sephadex G-25 column chromatography, the ScFv
was slowly added to the liposomes in the presence of a small mag-
netic stirring bar. Oxygen was displaced by running a slow stream of
nitrogen over the reaction mixture. The tube was capped and sealed
with Teflon tape, and the reaction mixture was incubated overnight
at room temperature with continuous slow stirring. The resulting
immunoliposomes were separated from unreacted ScFvs by
chromatography with the use of Sepharose CL-4B, sterilized by
filtration through 0.2-mm pore cellulose membranes (Millipore),
and stored at 4C until use. The antibody density was evaluated
by BioRad protein assay.
Particle size (in nanometers), polydispersity index (PdI), and zeta
potential (Z-potential in megavolts) of liposomal preparations
were measured at 25C using a Malvern Nano ZS90 light scat-
tering apparatus (Malvern Instruments) at a scattering angle of
90C.27–31 The physico-chemical features of this novel delivery
system are similar to those obtained in our previously publishedl or C1-3/DZNep liposome-treated liver. Right panel: graph showing percent positive
sentative control or C1-3/DZNep liposome-treated liver. Right panel: graph showing
A1, IL-6, CTGF, and angiopoetin 1 as quantified by qPCR in livers of control and
SEM. *p < 0.05, **p < 0.01.
Molecular Therapy Vol. 25 No 1 January 2017 227
Figure 7. Liposomes Coated with C1-3 ScAb and Loaded with DZNep
Reduce the Amount of H3K27me3 Present in Hepatic Myofibroblasts,
but Not Hepatocytes
(A) Histological sections showing H3K27me3 staining in a representative set of
control CSBD9/DZNep liposomes or C1-3/DZNep liposome-treated chronic CCl4
livers. Brown arrows, presence of H3K27me3 staining in hepatocytes in both
groups; red arrows, presence of H3K27me3 staining in myofibroblasts in CSBD9/
DZNep liposome-treated livers; blue arrows, point tomyofibroblasts in C1-3/DZNep
liposome-treated livers that have lost expression of this hitone mark due to the
targeted treatment. (B) Representative images show confocal maximum projections
of immunofluorescent-stained liver sections from chronic CCl4 injured mice treated
with CSBD9 or C1-3 coated liposomes, loaded with DZNep at 40 magnification
with 1.71 zoom. Sections are stained with DAPI (blue), anti H3K27me3 (red), and
anti aSMA (green). Yellow arrows, H3K27me3+ staining (red) in nuclei of aSMA+
cells (green); white arrows, H3K27me3 staining (red) in nuclei of aSMA+ cells
(green); red arrows, H3K27me3+ staining in hepatocytes. Scale bars, 43.63 mM.
Molecular Therapystudies performed with other encapsulated drugs and nucleic acid
liposomal formulations,27–31 thus indicating a possible clinical
translation.228 Molecular Therapy Vol. 25 No 1 January 2017Liver Fibrosis In Vivo Models: CCl4 and Free Drug DZNep
Treatment
Chronic CCl4 was injected intraperitoneally (i.p.) biweekly at 2 mL
(CCl4/olive oil, 1:3 (v/v))/g/body) for 8 weeks. From 2 weeks onward,
in addition to CCl4, mice received 150 mg/kg DZNep or vehicle
triweekly by i.p. injection for a further 6 weeks. Twenty-four hours
after the final CCl4 administration, animals were terminated and liver
and serum samples were prepared.
Liver Fibrosis In Vivo Models: CCl4 and Liposomal DZNep
Treatment
Chronic CCl4 was injected intraperitoneally (i.p.) biweekly at 2 mL
(CCl4/olive oil, 1:3 (v/v))/g/body) for 8 weeks. From 2 weeks onward,
in addition to CCl4, mice received 200 mL of liposomal DZNep
preparation coated with C1-3 single chain antibody (ScAb) or
CSBD9 control ScAb triweekly by intravenous (i.v.) injection for a
further 6 weeks. Twenty-four hours after the final CCl4 administra-
tion, animals were terminated and liver and serum samples were
prepared.
RNA Isolation and qRT-PCR
Total RNA was isolated from approximately 200 mg of frozen livers
or from5 106 cultured cells using the Total RNA Purification Kit
(QIAGEN). First-strand complementary DNA was generated by us-
ing 1 mg of deoxyribonuclease-treated RNA, 1 mL of random hexamer
primer (p(dN)6), and ribonuclease-free water (QIAGEN) heated at
70C for 5 min and then placed on ice. RNasin (ribonuclease inhibi-
tor), 100 U of Moloney murine leukemia virus reverse transcriptase,
1  Moloney murine leukemia virus buffer, and 0.4 mmol/L deoxy-
nucleoside triphosphates were added, and the mix was incubated at
42C for 1 hr. SYBR Green qRT-PCR was performed using the
primers listed in Table 1.
qPCR
SYBR Green qRT-PCR reactions were performed in a total volume of
13 mL containing 20 ng of cDNA template, 6.5 mL of SYBR Green
JumpStart Taq ReadyMix (Sigma), and 20 pmols of forward and
reverse primers (Table 1). The PCR reaction was carried out on a
7500 Fast Real-Time PCR System (Applied Biosystem) with the
following parameters: 1 cycle at 95C for 10 s followed by 40 cycles
at 95C for 10 s, 55C–60C (primer pair specific annealing temper-
ature, see Tables 1 and S1) for 30 s, and finally 72C for 30 s. Melt
curve analysis was employed to confirm the presence of a single
PCR product. All reactions were normalized to rat b-actin or human
GAPDH internal control, and the relative level of transcriptional dif-
ference was calculated using the 2DDCt method.
Sodium Dodecyl Sulfate: Polyacrylamide Gel Electrophoresis
and Immunoblotting
Whole-cell extracts were prepared, and the protein concentration
of samples was determined by using a Bradford DC assay kit
(Bio-Rad). Whole-cell extracts from samples of interest were then
fractionated by electrophoresis through a 9% sodium dodecyl sul-
fate-polyacrylamide gel. Gels were run at 100 V for 1.5 hr before
Table 1. qPCR Primers
Gene Forward and Reverse Primer Pair Sequences
Annealing
Temperature (C)
Mouse
Collagen 1A1
TTCACCTACAGCACGCTTGTG
58
GATGACTGTCTTGCCCCAAGTT
Mouse CTGF
CAAAGCAGCTGCAAATACCA
58
GGCCAAATGTGTCTTCCAGT
Mouse
TIMP- 1
GCAACTCGGACCTGGTCATAA
58
CGGCCCGTGATGAGAAACT
Mouse IL-6
GAGGATACCACTCCCAACAGACC
58
AAGTGCATCATCGTTGTTCATACA
Mouse TGFb 1
CTCCCGTGGCTTCTAGTGC
58
GCCTTAGTTTGGACAGGATCTG
Mouse a SMA
TCAGCGCCTCCAGTTCCT
58
AAAAAAAACCACGAGTAACAAATCAA
Mouse Slpi
GTGGAAGGAGGCAAAAATGA
58
GACATTGGGAGGGTTAAGCA
Mouse
HAMP2
CTGCCTGTCTCCTGCTTCTC
58
GCAGATGGGGAAGTTGATGT
Mouse G6pC
TCTGTCCCGGATCTACCTTG
58
GTAGAATCCAAGCGCGAAAC
Mouse Thrsp
ACGGAGCCCCTGATCTCTAT
58
GGCTTCTAGGTCCAGCTCCT
Mouse
GAPDH
GCACAGTCAAGGCCGAGAAT
58
GCCTTCTCCATGGTGGTGAA
Mouse
angiopoietin 1
AGGCTTGGTTTCTCGTCAGA
56
TCTGCACAGTCTCGAAATGG
www.moleculartherapy.orgtransfer onto nitrocellulose. After thr blockade of nonspecific protein
binding, nitrocellulose blots were incubated for 1 hr with primary an-
tibodies diluted in Tris-buffered saline (TBS)/Tween 20 (0.075%)
containing 5% bovine serum albumin. Rabbit polyclonal antibody-
recognizing EZH2 was used at 1/500 dilution (Active Motif, catalog
no. 39103), H3K27me2 (Abcam ab24684), H3K27me3 (Abcam,
ab6002), H3K4me3 (Abcam, ab8580), and b-actin at 1/1000 dilution
(Sigma). After incubation with primary antibodies, blots were washed
three times in TBS/Tween 20 before incubation for 1 hr in appropriate
horseradish peroxidase-conjugated secondary antibody. After exten-
sive washing in TBS/Tween 20, the blots were processed with distilled
water for detection of antigen by using the enhanced chemilumines-
cence system (Amersham Biosciences).
Microarray
Chronic CCl4 control or DZNep-treated livers (as outlined in the liver
fibrosis in vivo models) were used to prepare total RNA, which was
utilized for ILMR8 Illumina service MouseRef-8 v2.0 Expression
BeadChip. Analysis of microarray data was performed using R
from Bioconductor, which has superior normalization specific for il-
lumina arrays (http://www.bioconductor.org/packages/2.10/bioc/
html/lumi.html). Following this stage, Rank Prod was used togenerate a list of differentially expressed genes. (http://www.
bioconductor.org/packages/2.10/bioc/html/RankProd.html).
MTT Assay
Solutions of 3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyl tetrazolium
bromide (MTT) were dissolved in cell culture medium. HSC
treated ± DZNep were seeded at 1 105/mL per well in a 12-well tis-
sue culture plate (Greiner) and cultured for 7 days. Cells were PBS
washed and then serum starved overnight in 0.1% serum containing
media. 100 mL stock of MTT (Sigma) salt (final concentration of
0.5 mg/mL in DPBS) was added to each well for 2 hr at 37C. Forma-
zan crystals formed were solubilized using 800 mL isopropanol with
gentle agitation at room temperature; 200 mL from each well was
transferred into a flat bottomed 96 well dish and then quantified using
a spectrophotometric plate reader at 570 nm/620 nm and analyzed
with SoftMax Pro software.
Quantification of Apoptosis
Apoptotic cells were identified and counted by acridine orange stain-
ing and counted as previously described.32 Acridine orange emits
green fluorescence when bound to double-stranded DNA (dsDNA)
in the FITC channel and red fluorescence when bound to single-
stranded DNA (ssDNA) or RNA in the Rhodamine channel. Images
were taken at 10 magnification using a Zeiss axio observer D.1.
Statistical Analysis
Data are expressed as mean ± SEM. All p values were calculated using
a two-tailed paired or unpaired Student t test. Statistically significant
data are represented in figures where *p < 0.05, **p < 0.01, and
***p < 0.001, respectively.
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